Lisa R Haddad

Lisa R. Haddad

PartnerCo-Chair, Public M&A / Corporate Governance
Lisa R. Haddad
+1 617 570 8311

Lisa Haddad is a partner and co-chair of the firm’s Public M&A / Corporate Governance practice. She focuses on mergers and acquisitions, corporate governance, securities offerings, securities law compliance for public companies, and general corporate matters. Ms. Haddad serves on the firm’s Allocations Committee. She was formerly a member of the firm’s Executive Committee and co-chair of Goodwin’s Women’s Initiative.


Ms. Haddad has extensive experience in representing buyers, sellers and financial advisors in merger and acquisition transactions involving both public and private companies, especially in the life sciences and technology sectors. In this area, she has a special focus on public company mergers and acquisitions and other complex transactions involving public companies. Ms. Haddad also advises public companies on a wide variety of corporate and securities matters and represents public companies as general corporate and securities law counsel. In that capacity, she provides advice in all aspects of corporate governance and securities law compliance.

Her recent experience includes representing:

  • Citrix Systems in its $16.5 billion pending sale to Vista Equity Partners and Evergreen Coast Capital
  • Mimecast in its $5.8 billion sale to Permira
  • Trillium Therapeutics in its $2.3 billion sale to Pfizer
  • MyoKardia in its $13.1 billion sale to Bristol Myers Squibb
  • Special Committee of NantKwest in NantKwest’s merger with ImmunityBio
  • Spark Therapeutics in its $4.4 billion sale to Roche
  • Centerbridge Partners in its $1.4 billion acquisition of Civitas Solutions
  • Ipsen in its $1.3 billion (upfront cash and CVR) acquisition of Clementia Pharmaceuticals
  • Foundation Medicine in its $1.0 billion sale of a majority stake to Roche and subsequent $2.4 billion negotiated tender offer for the public minority interest by Roche
  • PTC in connection with a strategic partnership and $1.0 billion investment by Rockwell Automation
  • First Eagle Investment Management in its $500 million (upfront cash and CVR) acquisition of NewStar Financial
  • Neustar in its $2.9 billion sale to Golden Gate Capital 
  • Cornerstone OnDemand in connection with a $300 million strategic investment led by Silver Lake
  • Citrix Systems in a $2.9 billion Reverse Morris Trust transaction involving the merger of a division of Citrix with LogMeIn
  • LoJack Corporation in its $135 million sale to CalAmp Corp.
  • Teva Pharmaceutical in its $3.2 billion acquisition of Auspex Pharmaceuticals
  • Trulia in its $3.5 billion sale to Zillow
  • Eloqua in its $1.0 billion sale to Oracle
  • Citrix Systems in its cooperation agreement with Elliott Management
  • Cognex Corporation in the sale of its surface inspection systems division to AMETEK
  • Teva Pharmaceutical in the sale of its animal health division to Bayer
  • Haemonetics Corporation in its acquisition of Pall Corporation's blood collection, filtration and processing product lines




Harvard Law School

(magna cum laude)

Bachelor in Business Administration1993

University of Massachusetts Amherst

(cum laude)



  • Massachusetts

Recognition & Awards

Ms. Haddad has been recognized by:

  • The Best Lawyers in America Best Lawyers for 2023
  • Chambers USA 2022 for her work in Corporate/M&A
  • The Deal’s Top Women in Dealmaking list for 2022
  • The American Lawyer as a 2022 Northeast Trailblazer
  • BTI Consulting Group as a 2022 BTI Client Service All-Star
  • The Legal 500 as a 2021 recommended lawyer for Corporate Governance and Shareholder Activism: Advice to Boards


Ms. Haddad is a co-director of Goodwin’s Annual Directors Forum, an educational program designed for directors of public companies, and GOOD Directors, a leadership program focused on accelerating diversity in the boardroom. She also speaks at various board education programs and legal seminars on topics in her areas of practice.